Media Contacts:
Shannon Oates-Rivera
Teva Pharmaceuticals
484-318-0512
Teva Pharmaceuticals Sponsors Asthma Awareness Night at the Philadelphia Phillies
Company raises asthma awareness in local community
PHILADELPHIA, Pa., May 14, 2012 – On Monday, May 14, 2012, Teva Respiratory will sponsor Asthma Awareness Night at the Philadelphia Phillies game at Citizen’s Bank Park, as has been done for the past several years given the challenge of asthma in the surrounding area. On this special evening during Asthma Awareness Month, fans will receive ProAir® HFA/Phillies hats and can participate in free asthma screenings at stations throughout the ballpark.
Teva employee, Marilee Kartje, will throw out the ceremonial first pitch of the game. Marilee represents $18,880 collected from Teva employees in support of the American Lung Association (ALA) for the Philadelphia Fight for Air Walk that was held May 5, 2012.
During the game, fans can also participate in asthma screenings conducted by the American College of Allergy, Asthma & Immunology (ACAAI) located in three sections of the stadium.
“Teva Respiratory is committed to providing patients with access to asthma and nasal allergy medications. We are passionate about the work we do and are proud to offer medicines that ultimately help people breathe,” said Mark Salyer, executive vice president and general manager, Teva Respiratory.
Teva Respiratory offers treatment options for individuals with asthma, EIB, COPD, and nasal allergies and is committed to providing access to quality healthcare around the world.
MEDIA: Phillies credentials are needed to access the ballpark. To request a credential, please email Deanna Sabec at dsabec@phillies.com. If you are unfamiliar with the venue, please mention that in your email and someone will escort you to the field.
About Teva Respiratory
Teva Respiratory is the U.S.-based respiratory subsidiary of Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic version of Protonix® the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®, the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of Cephalon), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in our Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.
###